When is Zilucoplan expected to be launched in China?

Zilucoplan (Zilucoplan) is a synthetic peptide complement C5 inhibitor developed by UCB Pharma. In recent years, it has attracted widespread attention in the field of global neuroimmunotherapy. It is mainly used to treat generalized myasthenia gravis (gMG; rare disease), a rare neuromuscular disease caused by abnormalities in the autoimmune system and characterized by symptoms such as muscle weakness, difficulty swallowing, and restricted breathing. Zeleptide highly selectively blocks the C5 protein in the complement system, preventing it from further activating C5a and C5b, thereby inhibiting the formation of the membrane attack complex (MAC), thereby effectively reducing the inflammatory response at the neuromuscular junction, significantly improving patient symptoms and improving quality of life.

At present, zeleptide has submitted marketing applications in Europe and the United States and other countries, and was approved by the FDA in the United States at the end of 2023, becoming the second C5 complement inhibitor to be officially approved for the treatment of gMG after eculizumab. Its daily subcutaneous injection of 2 mg is more convenient than traditional intravenous infusion of drugs, and also improves patient compliance. In addition to gMG, zeleptide has also shown potential in other complement-mediated diseases such as PNH (paroxysmal nocturnal hemoglobinuria) and neuromyelitis optica spectrum diseases, and its indications are gradually expanding.

As far as the Chinese market is concerned, Zeleputide has not yet been officially approved for marketing by the National Medical Products Administration (NMPA), so it will not be available through formal channels in the short term. Factors affecting the drug's launch in China mainly include the lack of localized clinical trial data, the long drug registration review process, and approval policy factors such as whether to include the priority review green channel. Even if a drug has been approved in Europe and the United States, Chinese regulatory agencies usually still need to conduct population-adapted correlation analysis and safety assessment before promoting the marketing process.

Reference materials:https://www.drugs.com/zilucoplan.html